Virus-Specific Immune Response in HBeAg-Negative Chronic Hepatitis B: Relationship with Clinical Profile and HBsAg Serum Levels

The immune impairment characterizing chronic hepatitis B (cHBV) infection is thought to be the consequence of persistent exposure to viral antigens. However, the immune correlates of different clinical stages of cHBV and their relation with different levels of HBsAg have not been investigated. The a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one Jg. 8; H. 6; S. e65327
Hauptverfasser:	Loggi, Elisabetta, Bihl, Florian K., Cursaro, Carmela, Granieri, Camilla, Galli, Silvia, Brodosi, Lucia, Furlini, Giuliano, Bernardi, Mauro, Brander, Christian, Andreone, Pietro
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Public Library of Science 04.06.2013 Public Library of Science (PLoS)
Schlagworte:	Acquired immune deficiency syndrome Adult Aged AIDS Antigens Biology Care and treatment Carriers Chemiluminescence Chronic infection Deoxyribonucleic acid Disease susceptibility DNA Enzyme-linked immunosorbent assay Female Gastroenterology Health aspects Hepatitis Hepatitis B Hepatitis B e antigen Hepatitis B e Antigens - blood Hepatitis B surface antigen Hepatitis B virus - drug effects Hepatitis B virus - immunology Hepatitis B virus - physiology Hepatitis B, Chronic - blood Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Hepatology HIV Human immunodeficiency virus Humans Immune response Immune system Immunoassay In vivo methods and tests Infection Infections Interferon Laboratories Leukocytes (mononuclear) Lymphocytes Lymphocytes T Male Medicine Middle Aged Patients Peptides Peripheral blood mononuclear cells Proteomes Serum levels Species Specificity T cells T-Lymphocytes - drug effects T-Lymphocytes - immunology Viral antigens Viral infections Viruses γ-Interferon Italy
ISSN:	1932-6203, 1932-6203
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!